ArticleInternational archives of allergy and immunology2012
Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy.
Article in International archives of allergy and immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A consensus parameter for the evaluation and management of angioedema in the emergency department.Academic emergency medicine : official journal of the Society for Academic Emergency Medicine · 2014Guideline
- Article
- The international WAO/EAACI guideline for the management of hereditary angioedema - The 2021 revision and update.The World Allergy Organization journal · 2022Article
- Therapeutic management of hereditary angioedema: past, present, and future.Balkan medical journal · 2021Article
- The International/Canadian Hereditary Angioedema Guideline.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2019Review
- Hereditary Angioedema: The Economics of Treatment of an Orphan Disease.Frontiers in medicine · 2018Review
- Acquired and hereditary forms of recurrent angioedema: Update of treatment.Allergologie select · 2018Review
- Use of a C1 Inhibitor Concentrate in Adults ≥65 Years of Age with Hereditary Angioedema: Findings from the International BerinertDrugs & aging · 2016Observational
- A Decade of Change: Recent Developments in Pharmacotherapy of Hereditary Angioedema (HAE).Clinical reviews in allergy & immunology · 2016Review
- High attack frequency in patients with angioedema due to C1-inhibitor deficiency is a major determinant in switching to home therapy: a real-life observational study.Orphanet journal of rare diseases · 2016Article
- Expert perspectives on hereditary angioedema: Key areas for advancements in care across the patient journey.Allergy & rhinology (Providence, R.I.) · 2016Article
- Self-administered C1 esterase inhibitor concentrates for the management of hereditary angioedema: usability and patient acceptance.Patient preference and adherence · 2016Review
- Canadian hereditary angioedema guideline.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014Article
- In pursuit of excellence: an integrated care pathway for C1 inhibitor deficiency.Clinical and experimental immunology · 2013Article
- WAO Guideline for the Management of Hereditary Angioedema.The World Allergy Organization journal · 2012Article
- The new era of C1-esterase inhibitor deficiency therapy.Current allergy and asthma reports · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundC1 inhibitor (C1INH) has recently been approved in the USA for the treatment of acute attacks in hereditary angioedema (HAE) patients. The literature suggests that treatment with C1INH is most effective when administered early in an attack. Home infusion of C1INH allows for the earliest possible intervention since patients can initiate therapy at the first sign of symptoms.
methodsWe performed an observational, prospective study on 39 subjects with HAE utilizing two groups of patients: one receiving on-demand C1INH replacement therapy in a medical facility and the other self-managing on-demand C1INH replacement therapy in the home setting under the supervision of a treating physician. All subjects completed online questionnaires weekly for 8 weeks.
resultsThere were statistically significant decreases in attack duration (p < 0.0001), pain medication use (p < 0.0001) and graded attack severity (p < 0.005) in the subjects who received C1INH in the home setting versus the clinic-based group. Attack frequency was similar between the groups. The home group experienced more frequent injection-related side effects; however, the clinic group noted more severe adverse events from C1INH.
conclusionPhysician-supervised self-managed C1INH replacement therapy is a safe and effective treatment for patients with HAE with potential benefits in diminishing attack duration and attack severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.